Tag: commissions

Binaural Technologies’ The Brain Song offers a 17-minute gamma brainwave and BDNF support audio program for adults seeking natural memory, focus, and cognitive resilience without pills or complex routines in 2025.

Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.

Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.

Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025

Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health.

Scientifically Formulated Nootropic Backed by 2025 Research for Sharper Focus and Cognitive Support

AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025

- Grew Total Revenue 2% Year-over-Year to $42 Million -

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

– Total Revenues increased 13.8% for the quarter over the prior year period to $60.3 million –
– Total Written Premium increased 14.4% for the quarter over the prior year period to $450.3 million –
– Organic Revenue Growth Rate* of 10.6% for the quarter –
– Net income of $9.0 million for the quarter –
– Adjusted EBITDA* increased 40.7% for the quarter over the prior year period to $15.1 million –

Transparency-Driven Supplement Aligns With Growing Demand for Natural, Purposeful Formulations Supporting Active Lifestyles